EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Localized scleroderma and related comorbidities: a single-centre cohort study

Saara Kortelainen iD, Niina Hieta iD, Tiia Rissanen iD, Johanna Paltta iD, Laura Pirilä iD, Veli-Matti Kähäri iD

British Journal of Dermatology · 27.01.2026 · 194 (2) · 351-358

DOI: 10.1093/bjd/ljaf419 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 27.10.2025. Verfasst von Saara Kortelainen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland. Hauptthemen laut MEDLINE: Scleroderma, Localized, Autoimmune Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Turku University Hospital State Research, Research Council of Finland, Sigrid Jusélius Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Localized scleroderma, or morphoea, is a rare autoimmune disease that affects the skin and underlying tissue. It is more common in girls and women than in boys and men. The incidence has two peaks: one in childhood and another in middle-age. Concomitant autoimmune diseases are frequently observed, whereas systemic sclerosis occurs rarely simultaneously.

Objectives

To assess the clinical features, comorbidities and treatments of localized scleroderma in Southwest Finland.

Methods

Patients diagnosed with localized scleroderma (International Classification of Diseases, 10th Revision code L94) treated between 1 January 2005 and 30 November 2020 were identified from the hospital discharge register of Turku University Hospital, Turku, Finland. Diagnoses were classified into five main types and their subtypes based on the European Dermatology Forum criteria. Basic demographic data, associated comorbidities, and treatments used and their efficacy were recorded.

Results

A total of 155 people with morphoea were included, with 125 female patients (80.6%) and 30 male patients (19.4%). The most common subtype was limited, plaque-type morphoea (n = 71; 45.8%), followed by the generalized type (n = 57; 36.8%). Fifty-nine concomitant autoimmune diseases were identified in 45 patients (29.0%), most frequently autoimmune thyroid diseases (n = 23; 14.8%). Simultaneous systemic sclerosis was rare (n = 3; 1.9%). The most common malignancy was breast cancer (n = 11; 7.1%). Extracutaneous manifestations were more common in patients with paediatric-onset morphoea (n = 4/27; 14.8%) vs. those with adult-onset disease (n = 2/122; 1.6%). The most commonly used systemic treatment was methotrexate (n = 25; 16.1%), which was beneficial for 64% of the treated patients (n = 16). Phototherapy was administered in 63 of 155 patients (40.6%) and was beneficial in 49 (78%).

Conclusions

At our centre, patients with morphoea often require systemic immunomodulatory treatment or phototherapy. The incidence of the generalized subtype and the occurrence of concomitant autoimmune diseases, particularly thyroid autoimmune diseases, is relatively high. No evidence of an increased risk of malignancy was found in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, LocalizedAutoimmune DiseasesHumansMaleFemaleMiddle AgedAdultComorbidityAgedFinlandChildAdolescentYoung AdultIncidenceRetrospective StudiesChild, PreschoolImmunosuppressive Agents

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Centre for Rheumatology and Clinical Immunology, Division of Medicine, Turku University Hospital, Turku, Finland.
  • Department of Medicine, University of Turku, Turku, Finland.
  • Department of Dermatology, University of Turku, and Turku University Hospital, Turku, Finland.
  • Department of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland.

ORCID-Profile: Saara Kortelainen, Niina Hieta, Tiia Rissanen, Johanna Paltta, Laura Pirilä, Veli-Matti Kähäri

Förderung

  • Turku University Hospital State Research
  • Research Council of Finland
  • Sigrid Jusélius Foundation

Zitieren

APA

Kortelainen, S., Hieta, N., Rissanen, T., Paltta, J., Pirilä, L., & Kähäri, V. M. (2026). Localized scleroderma and related comorbidities: a single-centre cohort study. British Journal of Dermatology, 194(2), 351-358. https://doi.org/10.1093/bjd/ljaf419

Vancouver

Kortelainen S, Hieta N, Rissanen T, Paltta J, Pirilä L, Kähäri VM. Localized scleroderma and related comorbidities: a single-centre cohort study. British Journal of Dermatology. 2026;194(2):351-358. doi:10.1093/bjd/ljaf419

BibTeX
@article{Kortelainen2026,
  author = {Kortelainen, Saara and Hieta, Niina and Rissanen, Tiia and Paltta, Johanna and Pirilä, Laura and Kähäri, Veli-Matti},
  title = {Localized scleroderma and related comorbidities: a single-centre cohort study},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {194},
  number = {2},
  pages = {351--358},
  doi = {10.1093/bjd/ljaf419}
}
Kostenlos starten →